Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 1 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 2 (50%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOLAN, JASON MICHAEL | 1 | 66.5% | -28.1% |
| JOHNSON, CHRISTOPHER LINDSAY | 1 | 48.4% | +80.0% |
| HUI, SAN MING R | 1 | 59.5% | +20.1% |
| LEE, WILLIAM Y | 1 | 47.9% | +34.1% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18825194 | PRODRUGS OF GANAXOLONE | NOLAN, JASON MICHAEL | — |
| 18591515 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX | HUI, SAN MING R | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18785310 | GANAXOLONE FOR USE IN TREATMENT OF SUPER REFRACTORY STATUS EPILEPTICUS | JOHNSON, CHRISTOPHER LINDSAY | — |
| 18591515 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX | HUI, SAN MING R | — |
| 18328996 | USE OF GANAXOLONE IN TREATING AN EPILEPSY DISORDER | LEE, WILLIAM Y | — |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18825194 | PRODRUGS OF GANAXOLONE | NOLAN, JASON MICHAEL | — | §102§112 | Non-Final OA | — | Pending | Sep 05, 2024 |
| 18785310 | GANAXOLONE FOR USE IN TREATMENT OF SUPER REFRACTORY STATUS EPILEPTICUS | JOHNSON, CHRISTOPHER LINDSAY | — | §103DP | Non-Final OA | — | Pending | Jul 26, 2024 |
| 18591515 | GANAXOLONE FOR USE IN TREATING TUBEROUS SCLEROSIS COMPLEX | HUI, SAN MING R | — | §103§112Other | Non-Final OA | — | Pending | Feb 29, 2024 |
| 18328996 | USE OF GANAXOLONE IN TREATING AN EPILEPSY DISORDER | LEE, WILLIAM Y | 1623 | §102§103§112DP | Non-Final OA | — | Pending | Jun 05, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial